Search

Your search keyword '"Ilieva, Rumyana"' showing total 9 results
Start Over Author "Ilieva, Rumyana"
9 results on '"Ilieva, Rumyana"'

1. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial

Author

Pignata, Sandro, Oza, Amit, Hall, Geoff, Pardo, Beatriz, Madry, Radoslaw, Cibula, David, Klat, Jaroslav, Montes Worboys, Ana, Glasspool, Rosalind, Colombo, Nicoletta, Pete, Imre, Herrero Ibáñez, Ana, Romeo Marín, Margarita, Ilieva, Rumyana, Timcheva, Constanta, Maio, Massimo di, Blakeley, Christopher, Taylor, Rosie, Barnicle, Alan, Clamp, Andrew, Pignata, S, Oza, A, Hall, G, Pardo, B, Madry, R, Cibula, D, Klat, J, Montes, A, Glasspool, R, Colombo, N, Pete, I, Herrero Ibáñez, A, Marín, M, Ilieva, R, Timcheva, C, Di Maio, M, Blakeley, C, Taylor, R, Barnicle, A, and Clamp, A

Subjects
Olaparib, Oncology, Maintenance, Ovarian cancer, BRCA mutation, Càncer d'ovari, Genetics, Obstetrics and Gynecology, HRR, Genètica
Abstract

Background: The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after ≥2 lines of treatment. Methods: Patients received maintenance olaparib capsules (400mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. The co-primary endpoints were investigator-assessed progression-free survival (PFS; modified Response Evaluation Criteria in Solid Tumors v1.1) in BRCAm and sBRCAm cohorts. Secondary endpoints included health-related quality of life (HRQoL) and tolerability. Results: 177 patients received olaparib. At the primary data cut-off (17 April 2020), the median follow-up for PFS in the BRCAm cohort was 22.3months. The median PFS (95% CI) in BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts was 18.0 (14.3-22.1), 16.6 (12.4-22.2), 19.3 (14.3-27.6) and 16.4 (10.9-19.3) months, respectively. Most patients with BRCAm reported improvements (21.8%) or no change (68.7%) in HRQoL and the safety profile was as expected. Conclusions: Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC.

Published
2023

2. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Author

Nuran Katgi, Z. Andric, Elena Poddubskaya, Rita de Cassia Costamilan, Chaiyut Charoentum, Eduardo P Yañez Ruiz, Tamta Makharadze, Andrea Fulop, Susana Millan, D. Trukhin, Ana Del Campo García, Ravi Shankar Bellala, Yamil Alonso Lopez Chuken, Kostas N. Syrigos, Alexandra Paravisini, Amalia Florez, Jasmin Reyes-Igama, Irfhan Ali Hyder Ali, Stella Investigators, and Ilieva Rumyana

Subjects
medicine.medical_specialty, Lung Neoplasms, Bevacizumab, Paclitaxel, Anemia, medicine.medical_treatment, Population, Gastroenterology, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Original Research Article, Lung cancer, Adverse effect, education, Biosimilar Pharmaceuticals, 030203 arthritis & rheumatology, Pharmacology, Chemotherapy, education.field_of_study, business.industry, General Medicine, medicine.disease, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Relative risk, business, Biotechnology, medicine.drug
Abstract

Background MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab). Objectives To confirm clinical similarity between MB02 and EU-bevacizumab, a comparability study was undertaken in the first-line treatment of stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). Patients and Methods This multinational, double-blind, randomized, phase III study (STELLA) compared MB02 or EU-bevacizumab (15 mg/kg) administered with chemotherapy (paclitaxel 200 mg/m2 and carboplatin AUC6) on Day 1 of every 3-week cycle for 6 cycles (Week 18), followed by MB02/EU-bevacizumab in blinded monotherapy until disease progression, unacceptable toxicity, death, withdrawal of consent or end of study (Week 52). The primary efficacy endpoint was objective response rate (ORR) evaluated by an independent radiological review committee (IRC) at Week 18 (intent-to-treat population). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety and immunogenicity. Results A total of 627 subjects were randomized 1:1 to MB02 (n = 315) or EU-bevacizumab (n = 312). ORR, assessed by the IRC at Week 18, was comparable in MB02 (40.3%) and EU-bevacizumab (44.6%) groups. ORR risk ratio of 0.910 (90% CI 0.780 to 1.060; 95% CI 0.758 to 1.092) and ORR risk difference of −4.02 (90% CI −10.51 to 2.47; 95% CI −11.76 to 3.71) were within the similarity predefined margins. There were no significant differences between MB02 and EU-bevacizumab groups in median PFS (36.0 vs 37.3 weeks, respectively; HR 1.187; 95% CI 0.98 to 1.44) and median OS (not achieved; HR 1.108; 95% CI: 0.83 to 1.49) at the end of study. The safety profile of MB02 and EU-bevacizumab regarding nature, frequency and severity of the adverse events (AE) was comparable. The most frequent grade ≥3 investigational-product-related AEs were hypertension and anemia, with a difference between treatment groups of

Published
2021

3. Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.

Author

Pignata, Sandro, primary, Oza, Amit M., additional, Hall, Geoff, additional, Pardo, Beatriz, additional, Madry, Radoslaw, additional, Cibula, David, additional, Klat, Jaroslav, additional, Montes, Ana, additional, Glasspool, Rosalind, additional, Colombo, Nicoletta, additional, Pete, Imre, additional, Herrero, Ana, additional, Romeo, Marga, additional, Ilieva, Rumyana Nedyalkova, additional, Timcheva, Constanta, additional, Di Maio, Massimo, additional, Barnicle, Alan, additional, Taylor, Rosemary, additional, Bashir, Zahid, additional, and Clamp, Andrew R., additional

Published
2022
Full Text
View/download PDF

4. ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status

Author

Pignata, Sandro, primary, Oza, Amit, additional, Hall, Geoff, additional, Pardo, Beatriz, additional, Madry, Radoslaw, additional, Cibula, David, additional, Klat, Jaroslav, additional, Montes, Ana, additional, Glasspool, Rosalind, additional, Colombo, Nicoletta, additional, Pete, Imre, additional, Herrero, Ana, additional, Marin, Margarita Romeo, additional, Ilieva, Rumyana, additional, Timcheva, Constanta, additional, Blakeley, Christopher, additional, Taylor, Rosie, additional, Barnicle, Alan, additional, and Clamp, Andrew, additional

Published
2021
Full Text
View/download PDF

5. Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Author

Stemmer, Salomon M., primary, Manojlovic, Nebojsa S., additional, Marinca, Mihai Vasile, additional, Petrov, Petar, additional, Cherciu, Nelly, additional, Ganea, Doina, additional, Ciuleanu, Tudor Eliade, additional, Pusca, Ioana Adriana, additional, Beg, Muhammad Shaalan, additional, Purcell, William T., additional, Croitoru, Adina-Emilia, additional, Ilieva, Rumyana Nedyalkova, additional, Natošević, Sladjana, additional, Nita, Amedeia Lavinir, additional, Kalev, Dimitar Nikolaev, additional, Harpaz, Zivit, additional, Farbstein, Motti, additional, Silverman, Michael H., additional, Bristol, David, additional, Itzhak, Inbal, additional, and Fishman, Pnina, additional

Published
2021
Full Text
View/download PDF

6. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Author

Goldman, Jonathan W, primary, Dvorkin, Mikhail, additional, Chen, Yuanbin, additional, Reinmuth, Niels, additional, Hotta, Katsuyuki, additional, Trukhin, Dmytro, additional, Statsenko, Galina, additional, Hochmair, Maximilian J, additional, Özgüroğlu, Mustafa, additional, Ji, Jun Ho, additional, Garassino, Marina Chiara, additional, Voitko, Oleksandr, additional, Poltoratskiy, Artem, additional, Ponce, Santiago, additional, Verderame, Francesco, additional, Havel, Libor, additional, Bondarenko, Igor, additional, Każarnowicz, Andrzej, additional, Losonczy, György, additional, Conev, Nikolay V, additional, Armstrong, Jon, additional, Byrne, Natalie, additional, Thiyagarajah, Piruntha, additional, Jiang, Haiyi, additional, Paz-Ares, Luis, additional, Voitko, Nataliia, additional, Kazarnowicz, Andrzej, additional, Özgüroglu, Mustafa, additional, Conev, Nikolay, additional, Hochmair, Maximilian, additional, Burghuber, Otto, additional, Çiçin, Irfan, additional, Moiseenko, Vladimir, additional, Erman, Mustafa, additional, Kowalski, Dariusz, additional, Wojtukiewicz, Marek, additional, Adamchuk, Hryhoriy, additional, Vasilyev, Alexander, additional, Shevnia, Serhii, additional, Valev, Spartak, additional, Insa Molla, Maria Amelia, additional, Ursol, Grygorii, additional, Chiang, Anne, additional, Hartl, Sylvia, additional, Horváth, Zsolt, additional, Pajkos, Gábor, additional, Kim, Sang-We, additional, Smolin, Alexey, additional, Göksel, Tuncay, additional, Dakhil, Shaker, additional, Roubec, Jaromir, additional, Bogos, Krisztina, additional, Cornelissen, Robin, additional, Lee, Jong-Seok, additional, Garcia Campelo, Maria Rosario, additional, Lopez Brea, Marta, additional, Alacacioglu, Ahmet, additional, Casarini, Ignacio, additional, Ilieva, Rumyana, additional, Tonev, Ivan, additional, Somfay, Attila, additional, Bar, Jair, additional, Zer Kuch, Alona, additional, Minelli, Mauro, additional, Bartolucci, Roberta, additional, Roila, Fausto, additional, Saito, Haruhiro, additional, Azuma, Koichi, additional, Lee, Gyeong-Won, additional, Luft, Alexander, additional, Urda, Michal, additional, Delgado Mingorance, Juan Ignacio, additional, Majem Tarruella, Margarita, additional, Spigel, David, additional, Koynov, Krassimir, additional, Zemanova, Milada, additional, Panse, Jens, additional, Schulz, Christian, additional, Pápai Székely, Zsolt, additional, Sárosi, Veronika, additional, Delmonte, Angelo, additional, Bettini, Anna Cecilia, additional, Nishio, Makoto, additional, Okamoto, Isamu, additional, Hendriks, Lizza, additional, Mandziuk, Slawomir, additional, Lee, Yun Gyoo, additional, Vladimirova, Lyubov, additional, Isla Casado, Dolores, additional, Domine Gomez, Manuel, additional, Navarro Mendivil, Alejandro, additional, Morán Bueno, Teresa, additional, Wu, Shang-Yin, additional, Knoble, Jeanna, additional, Skrickova, Jana, additional, Venkova, Violetka, additional, Hilgers, Werner, additional, Laack, Eckart, additional, Bischoff, Helge, additional, Fülöp, Andrea, additional, Laczó, Ibolya, additional, Kósa, Judit, additional, Telekes, András, additional, Yoshida, Tatsuya, additional, Kanda, Shintaro, additional, Hida, Toyoaki, additional, Hayashi, Hidetoshi, additional, Maeda, Tadashi, additional, Kawamura, Tetsuji, additional, Nakahara, Yasuharu, additional, Claessens, Niels, additional, Lee, Ki Hyeong, additional, Chiu, Chao-Hua, additional, Lin, Sheng-Hao, additional, Li, Chien-Te, additional, Demirkazik, Ahmet, additional, Schaefer, Eric, additional, Nikolinakos, Petros, additional, Schneider, Jeffrey, additional, Babu, Sunil, additional, Lamprecht, Bernd, additional, Studnicka, Michael, additional, Fausto Nino Gorini, Carlos, additional, Kultan, Juraj, additional, Kolek, Vitezslav, additional, Souquet, Pierre-Jean, additional, Moro-Sibilot, Denis, additional, Gottfried, Maya, additional, Smit, Egbert, additional, Lee, Kyung Hee, additional, Kasan, Peter, additional, Chovanec, Jozef, additional, Goloborodko, Olexandr, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Lakhanpal, Shailendra, additional, Haque, Basir, additional, Chua, Winston, additional, Stilwill, Joseph, additional, Sena, Susana Noemi, additional, Girotto, Gustavo Colagiovanni, additional, De Marchi, Pedro Rafael Martins, additional, Martinelli de Oliveira, Fabricio Augusto, additional, Dos Reis, Pedro, additional, Krasteva, Rositsa, additional, Zhao, Yanqiu, additional, Chen, Chengshui, additional, Koubkova, Leona, additional, Robinet, Gilles, additional, Chouaid, Christos, additional, Grohe, Christian, additional, Alt, Jürgen, additional, Csánky, Eszter, additional, Somogyiné Ezer, Éva, additional, Heching, Norman Isaac, additional, Kim, Young Hak, additional, Aatagi, Shinji, additional, Kuyama, Shoichi, additional, Harada, Daijiro, additional, Nogami, Naoyuki, additional, Nokihara, Hiroshi, additional, Goto, Hisatsugu, additional, Staal van den Brekel, Agnes, additional, Cho, Eun Kyung, additional, Kim, Joo-Hang, additional, Ganea, Doina, additional, Ciuleanu, Tudor, additional, Popova, Ekaterina, additional, Sakaeva, Dina, additional, Stresko, Marian, additional, Demo, Pavol, additional, Godal, Robert, additional, Wei, Yu-Feng, additional, Chen, Yen-Hsun, additional, Hsia, Te-Chun, additional, Lee, Kang-Yun, additional, Chang, Huang-Chih, additional, Wang, Chin-Chou, additional, Dowlati, Afshin, additional, Sumey, Christopher, additional, Powell, Steven, additional, Goldman, Jonathan, additional, Zarba, Juan Jose, additional, Batagelj, Emilio, additional, Pastor, Andrea Viviana, additional, Zukin, Mauro, additional, Baldotto, Clarissa Serodio da Rocha, additional, Schlittler, Luis Alberto, additional, Calabrich, Aknar, additional, Sette, Claudia, additional, Dudov, Asen, additional, Zhou, Caicun, additional, Lena, Hervé, additional, Lang, Susanne, additional, Pápai, Zsuzsanna, additional, Goto, Koichi, additional, Umemura, Shigeki, additional, Kanazawa, Kenya, additional, Hara, Yu, additional, Shinoda, Masahiro, additional, Morise, Masahiro, additional, Hiltermann, Jeroen, additional, Mróz, Robert, additional, Ungureanu, Andrei, additional, Andrasina, Igor, additional, Chang, Gee-Chen, additional, Vynnychenko, Ihor, additional, Shparyk, Yaroslav, additional, Kryzhanivska, Anna, additional, Ross, Helen, additional, Mi, Kailhong, additional, Jamil, Rodney, additional, Williamson, Michael, additional, Spahr, Joseph, additional, Han, Zhigang, additional, Wang, Mengzhao, additional, Yang, Zhixiong, additional, Hu, Jie, additional, Li, Wei, additional, Zhao, Jun, additional, Feng, Jifeng, additional, Ma, Shenglin, additional, Zhou, Xiangdong, additional, Liang, Zongan, additional, Hu, Yi, additional, Chen, Yuan, additional, Bi, Minghong, additional, Shu, Yongqian, additional, Nan, Kejun, additional, Zhou, Jianying, additional, Zhang, Wei, additional, Ma, Rui, additional, Yang, Nong, additional, Lin, Zhong, additional, Wu, Gang, additional, Fang, Jian, additional, Zhang, Helong, additional, Wang, Kai, additional, and Chen, Zhendong, additional

Published
2021
Full Text
View/download PDF

7. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Author

Paz-Ares, Luis, primary, Dvorkin, Mikhail, additional, Chen, Yuanbin, additional, Reinmuth, Niels, additional, Hotta, Katsuyuki, additional, Trukhin, Dmytro, additional, Statsenko, Galina, additional, Hochmair, Maximilian J, additional, Özgüroğlu, Mustafa, additional, Ji, Jun Ho, additional, Voitko, Oleksandr, additional, Poltoratskiy, Artem, additional, Ponce, Santiago, additional, Verderame, Francesco, additional, Havel, Libor, additional, Bondarenko, Igor, additional, Kazarnowicz, Andrzej, additional, Losonczy, György, additional, Conev, Nikolay V, additional, Armstrong, Jon, additional, Byrne, Natalie, additional, Shire, Norah, additional, Jiang, Haiyi, additional, Goldman, Jonathan W, additional, Batagelj, Emilio, additional, Casarini, Ignacio, additional, Pastor, Anea Viviana, additional, Sena, Susana Noemi, additional, Zarba, Juan Jose, additional, Burghuber, Otto, additional, Hartl, Sylvia, additional, Lamprecht, Bernd, additional, Studnicka, Michael, additional, Alberto Schlittler, Luis, additional, Augusto Martinelli de Oliveira, Fabricio, additional, Calabrich, Aknar, additional, Colagiovanni Girotto, Gustavo, additional, Dos Reis, Peo, additional, Fausto Nino Gorini, Carlos, additional, Rafael Martins De Marchi, Peo, additional, Serodio da Rocha Baldotto, Clarissa, additional, Sette, Claudia, additional, Zukin, Mauro, additional, Dudov, Assen, additional, Ilieva, Rumyana, additional, Koynov, Krassimir, additional, Krasteva, Rositsa, additional, Tonev, Ivan, additional, Valev, Spartak, additional, Venkova, Violetka, additional, Bi, Minghong, additional, Chen, Chengshui, additional, Chen, Yuan, additional, Chen, Zhendong, additional, Fang, Jian, additional, Feng, Jifeng, additional, Han, Zhigang, additional, Hu, Jie, additional, Hu, Yi, additional, Li, Wei, additional, Liang, Zongan, additional, Lin, Zhong, additional, Ma, Rui, additional, Ma, Shenglin, additional, Nan, Kejun, additional, Shu, Yongqian, additional, Wang, Kai, additional, Wang, Mengzhao, additional, Wu, Gang, additional, Yang, Nong, additional, Yang, Zhixiong, additional, Zhang, Helong, additional, Zhang, Wei, additional, Zhao, Jun, additional, Zhao, Yanqiu, additional, Zhou, Caicun, additional, Zhou, Jianying, additional, Zhou, Xiangdong, additional, Kolek, Vitezslav, additional, Koubkova, Leona, additional, Roubec, Jaromir, additional, Skrickova, Jana, additional, Zemanova, Milada, additional, Chouaid, Christos, additional, Hilgers, Werner, additional, Lena, Hervé, additional, Moro-Sibilot, Denis, additional, Robinet, Gilles, additional, Souquet, Pierre-Jean, additional, Alt, Jürgen, additional, Bischoff, Helge, additional, Grohe, Christian, additional, Laack, Eckart, additional, Lang, Susanne, additional, Panse, Jens, additional, Schulz, Christian, additional, Bogos, Krisztina, additional, Csánky, Eszter, additional, Fülöp, Anea, additional, Horváth, Zsolt, additional, Kósa, Judit, additional, Laczó, Ibolya, additional, Pajkos, Gábor, additional, Pápai, Zsuzsanna, additional, Pápai Székely, Zsolt, additional, Sárosi, Veronika, additional, Somfay, Attila, additional, Somogyiné Ezer, Éva, additional, Telekes, Anás, additional, Bar, Jair, additional, Gottfried, Maya, additional, Heching, Norman Isaac, additional, Zer Kuch, Alona, additional, Bartolucci, Roberta, additional, Bettini, Anna Cecilia, additional, Delmonte, Angelo, additional, Garassino, Marina Chiara, additional, Minelli, Mauro, additional, Roila, Fausto, additional, Atagi, Shinji, additional, Azuma, Koichi, additional, Goto, Hisatsugu, additional, Goto, Koichi, additional, Hara, Yu, additional, Hayashi, Hidetoshi, additional, Hida, Toyoaki, additional, Kanazawa, Kenya, additional, Kanda, Shintaro, additional, Kim, Young Hak, additional, Kuyama, Shoichi, additional, Maeda, Tadashi, additional, Morise, Masahiro, additional, Nakahara, Yasuharu, additional, Nishio, Makoto, additional, Nogami, Naoyuki, additional, Okamoto, Isamu, additional, Saito, Haruhiro, additional, Shinoda, Masahiro, additional, Umemura, Shigeki, additional, Yoshida, Tatsuya, additional, Claessens, Niels, additional, Cornelissen, Robin, additional, Heniks, Lizza, additional, Hiltermann, Jeroen, additional, Smit, Egbert, additional, Staal van den Brekel, Agnes, additional, Kowalski, Dariusz, additional, Mańdziuk, Slawomir, additional, Mróz, Robert, additional, Wojtukiewicz, Marek, additional, Ciuleanu, Tudor, additional, Ganea, Doina, additional, Ungureanu, Anei, additional, Luft, Alexander, additional, Moiseenko, Vladimir, additional, Sakaeva, Dina, additional, Smolin, Alexey, additional, Vasilyev, Alexander, additional, Vladimirova, Lyubov, additional, Anasina, Igor, additional, Chovanec, Jozef, additional, Demo, Pavol, additional, Godal, Robert, additional, Kasan, Peter, additional, Stresko, Marian, additional, Urda, Michal, additional, Cho, Eun Kyung, additional, Kim, Joo-Hang, additional, Kim, Sang-We, additional, Lee, Gyeong-Won, additional, Lee, Jong-Seok, additional, Lee, Ki Hyeong, additional, Lee, Kyung Hee, additional, Lee, Yun Gyoo, additional, Amelia Insa Molla, Maria, additional, Domine Gomez, Manuel, additional, Ignacio Delgado Mingorance, Juan, additional, Isla Casado, Dolores, additional, Lopez Brea, Marta, additional, Majem Tarruella, Margarita, additional, Morán Bueno, Teresa, additional, Navarro Mendivil, Alejano, additional, Paz-Ares Rodríguez, Luis, additional, Ponce Aix, Santiago, additional, Rosario Garcia Campelo, Maria, additional, Chang, Gee-Chen, additional, Chen, Yen-Hsun, additional, Chiu, Chao-Hua, additional, Hsia, Te-Chun, additional, Lee, Kang-Yun, additional, Li, Chien-Te, additional, Wang, Chin-Chou, additional, Wei, Yu-Feng, additional, Wu, Shang-Yin, additional, Alacacıoğlu, Ahmet, additional, Çiçin, Irfan, additional, Demirkazik, Ahmet, additional, Erman, Mustafa, additional, Göksel, Tuncay, additional, Adamchuk, Hryhoriy, additional, Kolesnik, Oleksii, additional, Kryzhanivska, Anna, additional, Ostapenko, Yuriv, additional, Shevnia, Serhii, additional, Shparyk, Yaroslav, additional, Ursol, Grygorii, additional, Voitko, Nataliia, additional, Vynnychenko, Ihor, additional, Babu, Sunil, additional, Chiang, Anne, additional, Chua, Winston, additional, Dakhil, Shaker, additional, Dowlati, Afshin, additional, Haque, Basir, additional, Jamil, Rodney, additional, Knoble, Jeanna, additional, Lakhanpal, Shailena, additional, Mi, Kailhong, additional, Nikolinakos, Petros, additional, Powell, Steven, additional, Ross, Helen, additional, Schaefer, Eric, additional, Schneider, Jeffrey, additional, Spahr, Joseph, additional, Spigel, David, additional, Stilwill, Joseph, additional, Sumey, Christopher, additional, and Williamson, Michael, additional

Published
2019
Full Text
View/download PDF

8. A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

Author

Stemmer, Salomon M., primary, Manojlovic, Nebojsa S., additional, Marinca, Mihai Vasile, additional, Petrov, Petar, additional, Cherciu, Nelly, additional, Ganea, Doina, additional, Ciuleanu, Tudor-Eliade, additional, Puscas, Ioana Adriana, additional, Beg, Muhammad Shaalan, additional, Purcell, William T., additional, Croitoru, Adina-Emilia, additional, Ilieva, Rumyana Nedyalkova, additional, Natošević, Sladjana, additional, Nita, Amedeia Lavinir, additional, Kalev, Dimitar Nikolaev, additional, Harpaz, Zivit, additional, Farbstein, Motti, additional, Silverman, Michael H., additional, Fishman, Pnina, additional, and Llovet, Josep M, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results